Nanosizing of drugs: Effect on dissolution rate

Research in Pharmaceutical Sciences

Volumn 10, Issue 2, 2015, Pages 95-108

  Dizaj, S Maleki ^a   Vazifehasl, Zh ^b   Salatin, S ^a   Adibkia, Kh ^b   Javadzadeh, Y ^b  

^a UNIVERSITY OF TABRIZ   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dissolution rate; Nanocrystal; Nanoparticle; Nanosizing; Nanosuspension

Indexed keywords

ALBENDAZOLE; ATOVAQUONE; AZITHROMYCIN; CELECOXIB; CILOSTAZOL; CIPROFLOXACIN; DRUG CARRIER; FELODIPINE; IBUPROFEN; INDOMETACIN; ITRACONAZOLE; MELOXICAM; MICONAZOLE; NANOCAPSULE; NANOCRYSTAL; NANOPARTICLE; NANOSPHERE; NANOSUSPENSION; NIFEDIPINE; NITRENDIPINE; OLMESARTAN; PIROXICAM; PRANLUKAST; QUERCETIN; SIMVASTATIN; UBIDECARENONE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG SOLUBILITY; NANOTECHNOLOGY; PARTICLE SIZE; SURFACE AREA; THICKNESS;

EID: 84936743969     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Bhadoriya SS, Mangal A, Madoriya N, Dixit P. Bioavailability and bioactivity enhancement of herbal drugs by Nanotechnology: a review. J Curr Pharm Res. 2011;8:1-7.
2. Chowdary K, Enturi V. Enhancement of dissolution rate and formulation development of Efavirenz tablets employing starch phosphate a new modified starch. Int J Pharm Sci Drug Res. 2011;3:80-83.
3. Sahu BO, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci. 2014;4:189-197.
4. Chaudhary A, Nagaich U, Gulati N, Sharma V, Khosa R. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: a recent review. J Adv Pharm Educ Res. 2012;2:32-67.
5. Jung JY, Yoo SD, Lee SH, Kim KH, Yoon DS, Lee KH. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm. 1999;187:209-218.
6. Carsten E, Kwang Jin K. Drug absorption studies: in situ, in vitro and in silico models. New York: Springer; 2008. p. 182-215.
7. Kawakami K. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Adv Drug Deliv Rev. 2012;64:480-495.
8. Raval AJ, Patel MM. Preparation and characterization of nanoparticles for solubility and dissolution rate enhancement of meloxicam. Intl R J of Pharmaceuticals. 2011;1:43-49.
9. Pandya P, Gattani S, Jain P, Khirwal L, Surana S. Co-solvent evaporation method for enhancement of solubility and dissolution rate of poorly aqueous soluble drug simvastatin: in vitro-in vivo evaluation. AAPS Pharm Sci Tech. 2008;9:1247-1252.
10. Maleki Dizaj S. Preparation and study of vitamin A palmitate microemulsion drug delivery system and investigation of co-surfactant effect. J Nanostruct Chem. 2013;3:59.
11. Nokhodchi A, Aliakbar R, Desai S, Javadzadeh Y. Liquisolid compacts: the effect of cosolvent and HPMC on theophylline release. Colloids Surf B Biointerfaces. 2010;79:262-269.
12. Jagdale SC, Jadhav VN, Chabukswar AR, Kuchekar BS. Solubility enhancement, physicochemical characterization and formulation of fast-dissolving tablet of nifedipine-betacyclodextrin complexes. Braz J Pharm Sci. 2012;48:131-145.
13. Dhanaraju MD, Kumaran KS, Baskaran T, Moorthy MS. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Drug Dev Ind Pharm. 1998;24:583-587.
14. Shulman M, Cohen M, Soto-Gutierrez A, Yagi H, Wang H, Goldwasser J, et al. Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin. PloS one. 2011;6:e18033.
15. Sabzevari A, Adibkia K, Hashemi H, De Geest B, Mohsenzadeh N, Atyabi F, et al. Improved antiinflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide. Invest Ophthalmol Vis Sci. 2013;54:5520-5526.
16. Tapas A, Kawtikwar P, Sakarkar D. Enhanced dissolution rate of felodipine using spherical agglomeration with Inutec SP1 by quasi emulsion solvent diffusion method. Res Pharm Sci. 2009;4:77-84.
17. Nili SF, N Bolourchian M. Crystal habit modification of meloxicam utilizing different alcoholic solvents and crystallization conditions. Res Pharm Sci. 2012;7:S317.
18. Patel A, Jones SA, Ferro A, Patel N. Pharmaceutical salts: a formulation trick or a clinical conundrum. Br J Cardiol. 2009;16:281-286.
19. Shukla V. Techniques for solubility enhancement of poorly soluble drugs: an overview. J Med Pharm App Sci. 2012;1:18-38.
20. Ajay S, Harita D, Tarique M, Amin P. Solubility and dissolution rate enhancement of curcumin using kollidon VA64 by solid dispersion technique. Int J Pharm Tech Res. 2012;4:1055-1064.
21. Ismail S, El-Mahdy M, Al-Kubati S. Enhancement of solubility and dissolution of nimesulide using solubilization, solid dispersion and complexation techniques. Bull Pharm Sci, Assiut University. 2009;32:321-338.
22. Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, et al. Bioavailability enhancement of a poorly watersoluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm. 2004;269:251-258.
23. Kakran M, Sahoo N, Li L. Dissolution enhancement of quercetin through nanofabrication, complexation, and solid dispersion. Colloids Surf B Biointerfaces. 2011;88:121-130.
24. Ramakrishna GS, Anji Reddy K, P BJRD, Rao PR, Bhavanam PR. Enhancement dissolution rate of iboprofen by solid dispersion method. J Innovative Trends Pharm Sci. 2010;1:204-206.
25. Roul L, Manna N, Parhi R, Sahoo S, Suresh P. Dissolution rate enhancement of alprazolam by solid dispersion. Indian J Pharm Educ Res. 2012;46:38-44.
26. Tabbakhian FH, Tavakoli N, Z Jamshidian. Dissolution enhancement of glibenclamide by solid dispersion: solvent evaporation versus a supercritical fluid-based solvent-antisolvent technique. Res Pharm Sci. 2014;9:337-350.
27. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm. 2007;341:26-34.
28. Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm. 2008;362:102-108.
29. Rajesh K, Rajalakshmi R, Umamaheswari J, Ashok Kumar CK. Liquisolid technique a novel approach to enhance solubility and bioavailability. Int J Biopharmaceutics. 2011;2:8-13.
30. Thadkala K, Voruganti S, Badari SR, Padman SC. Enhancement of Dissolution rate of nimesulide by liquisolid compaction technique. Int J Pharm Tech Res. 2012;4:1294-1302.
31. Javadzadeha Y, Siahi-Shadbada M, Barzegar-Jalalia M, Nokhodchia A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco. 2005 60:361-365.
32. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad M, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci. 2005;12;8:18-25.
33. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91-97.
34. Möschwitzer J. Particle size reduction technologies in the pharmaceutical development process. Am Pharm Rev. 2010;2010:54-59.
35. Mohammadi G, Nokhodchi A, Barzegar-Jalali M, Lotfipour F, Adibkia K, Ehyaei N, et al. Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces. 2011;88:39-44.
36. Javadzadeh Y, Ahadi F, Davaran S, Mohammadi G, Sabzevari A, Adibkia K. Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids Surf B Biointerfaces. 2010;1;81:498-502.
37. Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. App Nanosci. 2014;4:189-197.
38. Kesisoglou F, Panmai S, Wu Y. Nanosizing Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-644.
39. ®; a novel excipient to improve dissolution rate of poorly water soluble drug, celecoxib. Res Pharm Sci. 2012;7:S386.
40. Sigfridsson K, Lundqvist AJ, Strimfors M. Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm. 2011;37:243-251.
41. Nekkanti V, Vabalaboina V, Pillai R. Drug Nanoparticles-An Overview. In: Hashim AA, editor. The delivery of nanoparticles. Rijeka: INTECH; 2012. p. 111-132.
42. Li X, Gu L, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm. 2009;35:827-833.
43. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3-16.
44. Robertson A. The development of ideas on heterogeneous catalysis. Platinum Metals Rev. 1983;27:31-39.
45. D'Addio SM, Prud'homme RK. Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011;63:417-426.
46. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorlywatersolublecompounds. Eu J Pharm Sci. 2003;18:113-120.
47. Adibkia K, Barzegar-Jalali M, Nokhodchi A, Siahi Shadbad M, Omidi Y, Javadzadeh Y, et al. A review on the methods of preparation of pharmaceutical nanoparticles. Pharm Sci. 2010;15:303-314.
48. Sabzevari A, Adibkia K, Hashemi H, Hedayatfar A, Mohsenzadeh N, Atyabi F, et al. Polymeric triamcinolone acetonide nanoparticles as a new alternative in the treatment of uveitis: in vitro and in vivo studies. Eur J Pharm Biopharm. 2013;84:63-71.
49. Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. Antimicrobial activity of the metals and metal oxide nanoparticles. Mater Sci Eng. 2014;44:278-284.
50. Gulsun T, Gursoy R, Levent O. Nanocrystal technology for oral delivery of poorly water-soluble drugs. FABAD J Pharm Sci. 2009;34:55-65.
51. Rasenack N, Müller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19:1894-1900.
52. Nighute A, Bhise S. Enhancement of Dissolution rate of rifabutin by preparation of microcrystals using solvent change method. Int J Pharm Tech Res. 2009;1:142-148.
53. da Costa MA, Seiceira RC, Rodrigues CR, Hoffmeister CRD, Cabral LM, Rocha HVA. Efavirenz dissolution enhancement I: comicronization. Pharmaceutics. 2012;5:1-22.
54. Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci & Tech. 2007;4:139-153.
55. Yu X, Valmikinathan CM, Wang J, Rogers A, Hoffman J, Nalwa HS. Electrospun nanofibers for bioengineering applications. Encyclopedia of nanoscience and nanotechnology. 2011;13;559-583.
56. Saffie-Siebert R, Ogden J, Parry-Billings M. Nanotechnology approaches to solving the problems of poorly water-soluble drugs. Drug Dis World. 2005;2:1-71.
57. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses. 2012;4:488-520.
58. Thassu D, Pathak Y, Deleers M. Nanoparticulate drug-delivery systems: an overview. Boca Raton, Florida: CRC press; 2007. p. 1-4.
59. Dizaj SM, Jafar I S, Yari-Khosroshahi A. A sight on the current nanoparticle-based gene delivery vectors. Nanoscale Res Lett. 2014;9:252.
60. Adibkia K, Javadzadeh Y, Dastmalchi S, Mohammadi G, Niri FK, Alaei-Beirami M. Naproxen-eudragit RS100 nanoparticles: Preparation and physicochemical characterization. Colloids Surf B Biointerfaces. 2011;83:155-159.
61. Cavalli R, Leone F. Nanosuspensions A versatile drug delivery platform. Chim Oggi. 2013;31:46-49.
62. Mansouri M, Pouretedal HR, Vosoughi V. Preparation and characterization of Ibuprofen nanoparticles by using solvent/antisolvent precipitation. Open Confere. Proc. J. 2011;2:88-94.
63. Beg S, Swain S, Rizwan M, Irfanuddin M, Shobha Malini D. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv. 2011;8:691-702.
64. De Villiers MM, Aramwit P, Kwon GS. Nanotechnology in drug delivery. New York City: Springer; 2009. p. 3-105.
65. Gupta RB, Kompella UB. Nanoparticles technology drug delivery. New York: Taylor & Francis; 2006. p. 1-20.
66. Junghanns J-UA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295-310.
67. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4:403-416.
68. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285:135-146.
69. Rezaei Mokarram A, Kebriaee zadeh A, Keshavarz M, Ahmadi A, Mohtat B. Preparation and in-vitro evaluation of indomethacin nanoparticles. DARU. 2010;18:185-192.
70. Liu Y, Sun C, Hao Y, Jiang T, Zheng L, Wang S. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci. 2010;13:589-606.
71. Badawi AA, El-Nabarawi MA, El-Setouhy DA, Alsammit SA. Formulation and stability testing of itraconazole crystalline nanoparticles. AAPS Pharm Sci Tech. 2011;12:811-820.
72. Koradia DK, Parikh HR. Dissolution enhancement of albendazole through nanocrystal formulation. J Pharm Bioallied Sci. 2012;4:S62.
73. Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C, et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomedicine. 2012;7:5733-5744.
74. Ravichandran R. Development of an oral curcumin nanocrystal formulation. J Nanotech Eng Med 2012;3:ID:041007.
75. Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimcrob Agents Chemother. 2001;45:1771-1779.
76. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299:167-177.
77. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly watersoluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56-64.
78. Quan P, Xia D, Piao H, Piao H, Shi K, Jia Y, et al. Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. AAPS Pharm Sci Tech. 2011;12:1136-1143.
79. Lai F, Pini E, Angioni G, Manca M, Perricci J, Sinico C, et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm. 2011;79:552-558.
80. Wang L, Hao Y, Liu N, Ma M, Yin Z, Zhang X. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method. Drug Dev Ind Pharm. 2012;38:1381-1389.
81. Patel VR, Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2:81-87.
82. Adibkia K, Omidi Y, Siahi MR, Javadzadeh AR, Barzegar-Jalali M, Barar J, et al. Inhibition of endotoxin-induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther. 2007;23:421-432.
83. Athul PV. Preparation and characterization of simvastatin nanosuspension by homogenization method. Int J Pharm Tech Res. 2013;5:193-197.
84. Cerdeira AM, Mazzotti M, Gander B. Formulation and drying of miconazole and itraconazole nanosuspensions. Int J Pharm. 2013;443:209-220.
85. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorlywatersoluble compounds. Eu J Pharm Sci. 2003;18:113-120.
86. Nakarani M, Misra A, Patel J, Vaghani S. Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation. Daru. 2010;18:84-90.
87. Jain V, Kare P, Jain D, Singh R. Development and characterization of mucoadhesive nanosuspension of ciprofloxacin. Acta Pol Pharm. 2011;68:273-278.
88. Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci. 2011;3:426-434.
89. Hou CD, Wang JX, Le Y, Zou HK, Zhao H. Preparation of azithromycin nanosuspensions by reactive precipitation method. Drug Dev Ind Pharm. 2012;38:848-854.
90. Pandya VM, Patel JK, Patel DJ. Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design. Dissolution Tech. 2011;18:40-45.
91. Saltiel E, Ellrodt A, Monk J, Langley M. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1988;36:387-428.
92. Tsuji JS, Maynard AD, Howard PC, James JT, Lam C-w, Warheit DB, et al. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Sci. 2006;89:42-50.
93. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3:133-149.
94. Zimper U, Aaltonen J, Krauel-Goellner K, Gordon KC, Strachan CJ, Rades T. The influence of milling on the dissolution performance of simvastatin. Pharmaceutics. 2010;2:419-431.